相关实验视频

Updated: Jun 4, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

小分子APOL1抑制剂作为APOL1介导病的精密医学方法

Brandon Zimmerman¹, Leslie A Dakin², Anne Fortier²

¹Vertex Pharmaceuticals Incorporated, Boston, MA, USA. brandon_zimmerman@vrtx.com.

Nature communications

|January 2, 2025

概括

研究人员开发了针对阿波利波蛋白L1 (APOL1) 基因的新型抑制剂. 这一发现为APOL1介导病 (AMKD) 提供了潜在的新疗法,APOL1介导病是导致衰竭的主要原因.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

慢性病 (CKD) 影响全球健康,目前没有针对潜在原因的治疗方法.
APOL1基因变异 (G1/G2) 被确定为特定蛋白尿性病亚型的关键驱动因素.
通过APOL1介导的病 (AMKD) 代表着一个重要的未满足的医疗需求.

研究的目的:

为了研究抑制阿波利波蛋白L1 (APOL1) 对AMKD的治疗潜力.
开发和描述新的APOL1抑制剂.
为了验证APOL1在细胞损伤和损伤中的作用.

主要方法:

开发临床前测试以评估APOL1活动.
发现和描述具有药物类似性质的强效,特定的APOL1抑制剂.
在AMKD的转基因小鼠模型中评估APOL1抑制剂的疗效.

主要成果:

证实APOL1通道活动驱动着细胞损伤.
抑制APOL1通道活动有效地阻止了APOL1介导的细胞死亡.
临床前研究表明,在相关的小鼠模型中,损伤的减少.

结论:

APOL1通道抑制是AMKD的一个有前途的治疗策略.
临床前发现支持APOL1抑制剂在基因定义病中的临床潜力.
这些结果与先前的临床数据相结合,加强了APOL1通道阻塞的可行性.

更多相关视频

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...